Table 1 Baseline characteristics and interventions in the clinical trial of AIN of unknown aetiology
Description | Group A (Pred + Pla) N = 15 | Group B (Dox + Pla) N = 15 | Group C (Pred + Dox) N = 14 | Group D (Pla + Pla) N = 15 | P-value |
|---|---|---|---|---|---|
Age median (IQR) years | 44 (36–52) | 47 (35–50) | 48 (35–50) | 47(38–52) | 0.9 |
Number of males (%) | 12 (80%) | 14 (100%) | 14 (93%) | 15(100%) | 0.1 |
Renal function [eGFR ml/min/1.73m2] median (IQR) | 47 (37–52) | 42 (33–52) | 50 (36–55) | 44 (29–52) | 0.7 |
Proteinuria [≥ 1 + DPU cases] (%) | 27 | 25 | 15 | 15 | 0.8 |
Hematuria (%) | 33 | 33 | 0.0 | 22 | 0.2 |
Leukocyturia (%) | 86 | 38 | 64 | 50 | 0.3 |
ESR (> 20 mm/h) median (IQR) | 42 (23–55) | 19 (15–35) | 49 (30–66) | 22 (14–39) | 0.3 |
CRP—> 10 mg/L (%) | 36 | 14 | 21 | 36 | 0.5 |
MAT titre [> 1:100 cases] (%) | 33 | 100 | 33 | 38 | 0.08 |
MBPL, median (IQR), cm | 9.6 (9.1–9.9) | 9.4 (8.2–9.9) | 9.6 (9.3–9.8) | 9.5 (9.3–11) | 0.7 |